Navigation Links
Adamis Pharmaceuticals CEO Provides Update for Shareholders
Date:5/3/2013

naphylaxis, APC-1000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, a HFA inhaled nasal steroid product for the treatment of allergic rhinitis.  Product candidates currently in development within its biotechnology division include TeloB-VAX, a novel cell-based therapeutic cancer vaccine, and three drug product candidates, APC-100, APC-200, and APC-300, for the treatment of prostate cancer and inflammation.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the ability to fund future product development and business operations; future revenues expected from any of the company's product candidates, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; our ability to complete any future acquisitions of products, product candidates or technologies; and the intellectual property protection that may be afforded by any patents or patent applications relating to the company's technology.  Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov.  Except as required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.

Related Links: http://adamispharmaceuticals.com/

For Additional Information

David Marguglio
Senior Vice President, Corporate Development
Adamis Pharmaceuticals Corp.<
'/>"/>

SOURCE Adamis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
2. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
4. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
8. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
9. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
10. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Cambridge Semantics, the leading provider of ... named in the recent ‘Hype Cycle for Life Sciences ... report details key insights pertaining to the benefits in ... analysts Michael Shanler and Stephen Davies, “The use of ... relationships with scientific stakeholders, and support collaboration and innovation ...
(Date:9/23/2014)... 23, 2014 Marktech Optoelectronics has introduced ... violet emitters in the 280 nm wavelength range. This ... which range from 280nm to 405nm. These new devices ... as well as curing. Mark Campito, Marktech’s CEO states ... interest to manufacturers is that we offer it in ...
(Date:9/23/2014)... 23, 2014 New spin-out ... Innovations, Cambridge Innovation Capital and Johnson & Johnson ... genomics company focused on harnessing the potential of ... testing and treatment, today announced it has raised ... Innovations and including Cambridge Innovation Capital and Johnson ...
(Date:9/22/2014)... 2014 Research and Markets ... the "Global Biotechnology Reagents Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are chemical compounds ... to detect and examine another substance to provide ... laboratories to prepare, collect, and examine specimens from ...
Breaking Biology Technology:Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Marktech Introduces its New Line of Deep UV Emitters 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... via Single ... Platform, MirixaPro(SM), RESTON, Va. and WASHINGTON, Oct. ... creator of,the Diabetes Ten City Challenge and a partner in the ... that will,deliver all of APhA Foundation,s HealthMapRx commercial programs via,Mirixa. MirixaPro(SM) ...
... Oct. 9 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ... technology, ePRO and other services to the pharmaceutical,biotechnology, ... will release its 2008 third quarter results for ... 30, 2008 after the market closes.,After the release, ...
... CEL-SCI Corporation,(NYSE: CVM ) announced today ... facility for its lead drug Multikine(R). This dedicated,facility, ... Multikine that,will be used for CEL-SCI,s pivotal Phase ... head and neck cancer patients, and,subsequently for sale ...
Cached Biology Technology:Mirixa Corporation and the APhA Foundation Form Partnership 2Mirixa Corporation and the APhA Foundation Form Partnership 3eResearchTechnology, Inc. to Announce 2008 Third Quarter Results on October 30, 2008 2CEL-SCI Takes Delivery of New Manufacturing Facility 2
(Date:9/22/2014)... 2011 the Society of Environmental Toxicology and Chemistry (SETAC) ... and prioritize the scientific research needed to understand the ... the environment. The effort was extended, and results ... Society,s international journal, Integrated Environmental Assessment and Management ... a podcast interviewing the lead author of the study, ...
(Date:9/22/2014)... Additive manufacturing (AM), or 3D printing, has rapidly ... metal components strong enough for structural applications. However, ... as well as quality standards to test the ... technology. Engineers at the University of Pittsburgh,s Swanson ... modeling and simulation (M&S) technology and new qualification ...
(Date:9/22/2014)... and larger areas of sea ice melt in the summer ... it is thinner and more reduced. As the Arctic summers ... warming, because reduced sea ice in the Arctic will remove ... our results are representative, then sea ice plays a greater ... in future global CO2 budgets", says Dorte Haubjerg Sgaard, PhD ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3Arctic sea ice helps remove CO2 from the atmosphere 2
... Nov. 21, 2011 Already partnering with 43 of ... Top 100 Innovators, NineSigma today announced a record year ... is critical to their long-term growth. "The ... never hesitate in their quest to innovate," said Andy ...
... data from electronic tags, ear bone microchemistry and fisheries catch ... of the Atlantic influences the other side. Bluefin populations ... since 1950, according to the study published today in the ... estimates the number of Atlantic bluefin tuna remaining in the ...
... FLAGSTAFF, Ariz. More peer-reviewed scientific studies ... developments and operations are needed to adequately assess their ... scientific literature review conducted by the U.S. Geological Survey ... In their literature review, the authors of the paper, ...
Cached Biology News:Surging Demand for Innovation Services Leads to Record Expansion for NineSigma 2Surging Demand for Innovation Services Leads to Record Expansion for NineSigma 3New study provides comprehensive view of the status of Atlantic bluefin tuna 2New study provides comprehensive view of the status of Atlantic bluefin tuna 3Literature review on solar energy and wildlife impacts research 2
MHC Volumes 1 & 2...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: